A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)

Trial Profile

A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Oct 2016

At a glance

  • Drugs Ropinirole (Primary)
  • Indications Restless legs syndrome
  • Focus Adverse reactions; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 02 Nov 2012 Planned number of patients changed from 480 to 488 as reported by European Clinical Trials Database.
    • 02 Nov 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2005-000184-25).
    • 29 Jun 2012 Additional trial location added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top